Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GLP-1 based therapy for type 2 diabetes.

D K Arulmozhi1, B Portha

  • 1Department of Pharmacology, New Chemical Entity Research, Lupin Research Park, Village Nande, Taluk Mulshi, Pune 411042, Maharashtra, India. adk_bits@yahoo.com

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|February 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity.

Biochimica et biophysica acta·2015
Same author

Maternal diabetes, programming of beta-cell disorders and intergenerational risk of type 2 diabetes.

Diabetes & metabolism·2014
Same author

Early environmental factors, alteration of epigenetic marks and metabolic disease susceptibility.

Biochimie·2013
Same author

A euglycaemic/non-diabetic perinatal environment does not alleviate early beta cell maldevelopment and type 2 diabetes risk in the GK/Par rat model.

Diabetologia·2012
Same author

IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat.

Proceedings of the National Academy of Sciences of the United States of America·2009
Same author

The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes?

Molecular and cellular endocrinology·2008

Glucagon-like peptide 1 (GLP-1) therapies show promise for type 2 diabetes by enhancing insulin secretion and reducing glucose levels. This review explores GLP-1 mimetics and DPP-IV inhibitors, discussing their benefits and drawbacks for metabolic control.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is a global health challenge requiring novel therapeutic strategies.
  • Current T2DM treatments, including diet, exercise, and various drugs, have limitations in controlling metabolic abnormalities and preserving beta-cell function.
  • Glucagon-like peptide 1 (GLP-1), an incretin hormone, presents a promising target for T2DM management due to its multiple antihyperglycemic actions.

Purpose of the Study:

  • To review the therapeutic potential of Glucagon-like peptide 1 (GLP-1) based therapies for type 2 diabetes.
  • To summarize current preclinical and clinical developments in GLP-1 mimetics and dipeptidyl peptidase IV (DPP-IV) inhibitors.
  • To discuss the advantages and limitations of both GLP-1 mimetic and DPP-IV inhibitor strategies.

Related Experiment Videos

Main Methods:

  • Review of existing scientific literature on GLP-1 based therapies for T2DM.
  • Analysis of preclinical and clinical data for GLP-1 mimetics and DPP-IV inhibitors.
  • Comparative discussion of the benefits and drawbacks of these therapeutic approaches.

Main Results:

  • GLP-1 exhibits multiple glucose-lowering effects, including enhanced insulin secretion, suppressed glucagon release, delayed gastric emptying, and reduced food intake.
  • GLP-1 is rapidly degraded by enzymes, leading to the investigation of GLP-1 mimetics and DPP-IV inhibitors to prolong its action.
  • Both GLP-1 mimetics and DPP-IV inhibitors are under active development, offering distinct mechanisms to improve glycemic control in T2DM.

Conclusions:

  • GLP-1 based therapies, including mimetics and DPP-IV inhibitors, represent a significant advancement in T2DM treatment.
  • These novel agents offer potential for improved metabolic control and beta-cell preservation.
  • Further research and clinical evaluation are necessary to fully elucidate the long-term efficacy and safety profiles of these emerging therapies.